Posted by omeditors | Posted in ADCITRES | Posted on 29-04-2017
Many researchers have taken part in the advancement of cancer therapy, and one of them is Clay Siegall. Clay is the President and the CEO of Seattle Genetics, a firm that focuses on cancer research and treatment. The desire to help cancer patients has made Siegall work tirelessly over the years in search of effective cancer therapy. He has seen Seattle Genetics grow from a small entity into a giant research firm that is recognized worldwide. Having the extensive experience of more than 20 years in cancer research and drug development, Clay has numerous achievements under his sleeve.
His journey began when he decided to pursue a Bachelor’s Degree in Zoology and later a Ph. D in Genetics at George Washington University. After graduating, Clay Siegall secured a job with Bristol-Myers Squibb Pharmaceutical Research Institute as a Senior Research Investigator and later as a Principal Scientist. Clay has also worked for National Cancer Institute, National Health Institutes, Alder Bio-pharmaceutical and Mirna Therapeutics.
Later, he shifted to private research and launched the famed Seattle Genetics in 1998.
Seattle Genetics is a global leader in cancer therapy technologies, and it is known in the pharmaceutical industry for its antibody-drug conjugate, ADCETRIS. It was the first ADC product to be approved by FDA in 2011. Through the collaboration between Takeda Pharmaceutical Company and Seattle Genetics, the drug has been approved in more than 65 countries.
Despite these achievements, Clay Siegall and Seattle Genetics have not shown any signs of slowing down in their journey to fight cancer. For instance, Seattle has entered into multiple agreements with Genentech (Roche), Pfizer, AbbVie and GlaxoSmithKline to advance its ADC technology. Through the agreements, partnerships, and licenses, the company has generated more than $300 million to date. In addition, Clay Siegall has led fund-raising activities where he managed to secure more than $675 million through public and private financing.
The medical and scientific community has greatly benefited from the knowledge and experience of Clay Siegall. He has shared it in more than 70 scientific articles, research papers and book chapters regarding cancer research. Moreover, he serves as a member of the editorial board of several reputable scientific journals.